Rocket Pharmaceuticals Reports Officer/Director Changes

Ticker: RCKTW · Form: 8-K · Filed: Apr 29, 2025 · CIK: 1281895

Rocket Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyRocket Pharmaceuticals, Inc. (RCKTW)
Form Type8-K
Filed DateApr 29, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, officer-appointment, director-election

TL;DR

Rocket Pharma's board and execs are shuffling, with new appointments and compensation changes effective April 26.

AI Summary

Rocket Pharmaceuticals, Inc. filed an 8-K on April 29, 2025, reporting changes effective April 26, 2025. The filing indicates a departure of directors or certain officers, election of directors, appointment of certain officers, and updates to compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the changes are not provided in this excerpt.

Why It Matters

Changes in key leadership and compensation structures can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Officer and director changes, especially without immediate detailed explanations, can introduce uncertainty about company direction and stability.

Key Players & Entities

  • Rocket Pharmaceuticals, Inc. (company) — Registrant
  • Delaware (jurisdiction) — State of incorporation
  • April 26, 2025 (date) — Date of earliest event reported
  • April 29, 2025 (date) — Date of report

FAQ

What specific changes were made regarding directors and officers?

The filing indicates a departure of directors or certain officers, election of directors, and appointment of certain officers, but does not specify the individuals or their exact roles in this excerpt.

When were these changes effective?

The changes reported in the 8-K were effective as of April 26, 2025.

What is the nature of the updates to compensatory arrangements?

The filing mentions updates to compensatory arrangements of certain officers, but the specific details of these arrangements are not provided in this excerpt.

What is Rocket Pharmaceuticals, Inc.'s principal executive office address?

The principal executive offices are located at 9 Cedarbrook Drive, Cranbury, NJ 08512.

What is the company's SIC code?

The Standard Industrial Classification (SIC) code for Rocket Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 29, 2025 regarding ROCKET PHARMACEUTICALS, INC. (RCKTW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.